JP2005517040A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005517040A5 JP2005517040A5 JP2003567445A JP2003567445A JP2005517040A5 JP 2005517040 A5 JP2005517040 A5 JP 2005517040A5 JP 2003567445 A JP2003567445 A JP 2003567445A JP 2003567445 A JP2003567445 A JP 2003567445A JP 2005517040 A5 JP2005517040 A5 JP 2005517040A5
- Authority
- JP
- Japan
- Prior art keywords
- growth
- cell
- specific
- inhibitor
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35691202P | 2002-02-14 | 2002-02-14 | |
| US60/356,912 | 2002-02-14 | ||
| PCT/EP2003/001507 WO2003068265A1 (en) | 2002-02-14 | 2003-02-14 | Methods and compositions for treating hyperproliferative conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005517040A JP2005517040A (ja) | 2005-06-09 |
| JP2005517040A5 true JP2005517040A5 (https=) | 2006-03-30 |
| JP5053503B2 JP5053503B2 (ja) | 2012-10-17 |
Family
ID=27734705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003567445A Expired - Fee Related JP5053503B2 (ja) | 2002-02-14 | 2003-02-14 | 過増殖状態を処置するための方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1476192B1 (https=) |
| JP (1) | JP5053503B2 (https=) |
| CN (1) | CN100591355C (https=) |
| AT (1) | ATE360442T1 (https=) |
| AU (1) | AU2003205768A1 (https=) |
| BR (1) | BR0307629A (https=) |
| CA (1) | CA2476000A1 (https=) |
| DE (1) | DE60313434T2 (https=) |
| ES (1) | ES2283744T3 (https=) |
| PT (1) | PT1476192E (https=) |
| WO (1) | WO2003068265A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
| WO2005082415A2 (en) * | 2004-02-25 | 2005-09-09 | Dana Farber Cancer Institute, Inc. | Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth |
| EP2168968B1 (en) | 2004-04-02 | 2017-08-23 | OSI Pharmaceuticals, LLC | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| US7329495B2 (en) | 2004-06-09 | 2008-02-12 | Board Of Regents, The University Of Texas System | Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors |
| TW200613306A (en) | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
| CA2623125A1 (en) | 2005-09-20 | 2007-03-29 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
| WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
| JP2012519170A (ja) | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法 |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099364A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2011109572A2 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| CA2783665A1 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| EP2544672A1 (en) | 2010-03-09 | 2013-01-16 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| WO2012116040A1 (en) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
| WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| US9834575B2 (en) | 2013-02-26 | 2017-12-05 | Triact Therapeutics, Inc. | Cancer therapy |
| WO2015035410A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutic, Inc. | Cancer therapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ226799A (en) * | 1987-11-06 | 1991-08-27 | Oncogen | Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor |
| DE4129533A1 (de) * | 1991-09-05 | 1993-03-11 | Max Planck Gesellschaft | Mutierter wachstumsfaktorrezeptor als arzneimittel und seine verwendung zur behandlung von krebs |
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| CN1117097C (zh) * | 1998-05-29 | 2003-08-06 | 北京金赛狮生物制药技术开发有限责任公司 | 类胰岛素生长因子受体基因的反义核酸的抑癌作用 |
-
2003
- 2003-02-14 CN CN03803734A patent/CN100591355C/zh not_active Expired - Fee Related
- 2003-02-14 WO PCT/EP2003/001507 patent/WO2003068265A1/en not_active Ceased
- 2003-02-14 AU AU2003205768A patent/AU2003205768A1/en not_active Abandoned
- 2003-02-14 BR BR0307629-6A patent/BR0307629A/pt not_active IP Right Cessation
- 2003-02-14 EP EP03702642A patent/EP1476192B1/en not_active Expired - Lifetime
- 2003-02-14 AT AT03702642T patent/ATE360442T1/de active
- 2003-02-14 DE DE60313434T patent/DE60313434T2/de not_active Expired - Lifetime
- 2003-02-14 PT PT03702642T patent/PT1476192E/pt unknown
- 2003-02-14 CA CA002476000A patent/CA2476000A1/en not_active Abandoned
- 2003-02-14 JP JP2003567445A patent/JP5053503B2/ja not_active Expired - Fee Related
- 2003-02-14 ES ES03702642T patent/ES2283744T3/es not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005517040A5 (https=) | ||
| IL324294A (en) | Aryl-or heteroaryl-substituted benzene compounds | |
| NO20014519D0 (no) | Apomorfin- og sildenafilpreparat | |
| JP2002522485A5 (https=) | ||
| JP2009138003A5 (https=) | ||
| EP2210606A3 (en) | Compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases | |
| JP2016539156A5 (https=) | ||
| JP2008519047A5 (https=) | ||
| JP2012515184A5 (https=) | ||
| CA2387486A1 (en) | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders | |
| RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря | |
| JP2004537500A5 (https=) | ||
| JP2005508896A5 (https=) | ||
| JP2009518415A5 (https=) | ||
| RU2007119067A (ru) | Средство для лечения синдрома раздраженного кишечника с преобладанием диареи | |
| JP2002540148A5 (https=) | ||
| JP2005513105A5 (https=) | ||
| WO2006138317A3 (en) | Dosage regimen for prasugrel | |
| JP2005505605A5 (https=) | ||
| JP2001316293A5 (https=) | ||
| JP2005502690A5 (https=) | ||
| JP2002501021A5 (https=) | ||
| JP2004538239A5 (https=) | ||
| KR950703958A (ko) | Hiv 감염증을 치료하기 위한,다른 비뉴클레오사이드 역 전사효소 억제제와 혼합된 bhap 화합물의 용도(use of bhap compounds in combination with other non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infection) | |
| Wagner et al. | Liposome dependent delivery of S‐adenosyl Methionine to cells by liposomes: A potential treatment for liver disease |